Compare CPBI & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CPBI | SERA |
|---|---|---|
| Founded | 2023 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Precision Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.2M | 75.2M |
| IPO Year | 2023 | 2021 |
| Metric | CPBI | SERA |
|---|---|---|
| Price | $20.00 | $2.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.50 |
| AVG Volume (30 Days) | 4.8K | ★ 19.7K |
| Earning Date | 11-18-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 9.38 | ★ 32.32 |
| EPS | ★ 0.39 | N/A |
| Revenue | N/A | ★ $81,000.00 |
| Revenue This Year | N/A | $177.78 |
| Revenue Next Year | N/A | $755.56 |
| P/E Ratio | $51.26 | ★ N/A |
| Revenue Growth | N/A | ★ 5.19 |
| 52 Week Low | $15.56 | $1.56 |
| 52 Week High | $21.83 | $3.95 |
| Indicator | CPBI | SERA |
|---|---|---|
| Relative Strength Index (RSI) | 49.49 | 55.41 |
| Support Level | $19.73 | $1.96 |
| Resistance Level | $20.74 | $2.18 |
| Average True Range (ATR) | 0.23 | 0.07 |
| MACD | -0.09 | 0.00 |
| Stochastic Oscillator | 43.10 | 66.62 |
Central Plains Bancshares Inc operates as the bank holding company for Home Federal Savings and Loan Association of Grand Island that provides mortgage, consumer, commercial real estate, and commercial loans. The bank business consists mainly of accepting deposits from the general public and investing those deposits, together with funds generated from operations, in one- to four-family residential mortgage loans secured by properties located in primary market area, as well as commercial real estate loans. The company's revenue is derived from the business of banking.
Sera Prognostics Inc is a health diagnostic company. It is a women's health company utilizing the proprietary proteomics and bioinformatics platform, and data resources to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.